OTC Topicals Firm's Regulatory Problems More Than Skin Deep
This article was originally published in The Pink Sheet
FDA's warning letter submitted following an October 2016 at Phillips Co.'s Millerton, Okla., facility states that the company does not appear committed to correcting the GMP, labeling and branding problems Office of Regulatory Affairs officials found.
You may also be interested in...
Poor data integrity at Asian API firms, poor quality programs at foreign OTC firms and poor sterility assurance at US compounding pharmacies were the main factors leading US FDA to issue 110 drug GMP warning letters in 2016, a huge increase from prior years. Article is first of four-part series in our annual analysis.
Perrigo largely has resolved distribution problems, but shipping freight costs still are much higher than pre-pandemic and it must divest a wound-care brand before US regulators sign off on acquisition of HRA Pharma, says CEO Murray Kessler during J.P. Morgan conference.
“We are positioned to move forward with either the Bausch + Lomb or Solta IPO quickly when market conditions are right for each of them,” CEO Joseph Papa says at J.P. Morgan conference, but the firm’s “next step” in the process of separating the two businesses was filing with the SEC an IPO registration for Bausch + Lomb.